CA
TLX

Clearstead Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Clearstead Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4K Buy
+2,112
New +$21.5K ﹤0.01% 1744

Other funds holding TLX

PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Clearstead Advisors's TLX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 2,112 shares worth $24.4K. The stake represents ﹤0.01% of the portfolio and ranks #1744 among its holdings.

20 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Clearstead Advisors held 2,112 shares of Telix Pharmaceuticals worth $24.4K as of Q2 2026.
  • Telix Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1744 holding.
  • 20 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.